Hims & Hers Health (HIMS) Total Non-Current Liabilities (2020 - 2026)
Hims & Hers Health's (HIMS) quarterly Total Non-Current Liabilities came in at $1.8 billion in Q1 2026, up 431.74% year-on-year from $340.0 million in Q1 2025, and up 12.85% quarter-over-quarter from $1.6 billion in Q4 2025.
Hims & Hers Health (HIMS) Total Non-Current Liabilities (2020 - 2026) Analysis & Trends
Hims & Hers Health has disclosed Total Non-Current Liabilities across 7 years of filings, most recently posting $1.8 billion for Q1 2026.
- Total Non-Current Liabilities for Q1 2026 came in at $1.8 billion, up 431.74% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.8 billion (up 431.74% YoY), and the FY2025 annual result was $1.6 billion, up 594.06% from the prior year.
- Total Non-Current Liabilities came in at $1.8 billion for Q1 2026 at Hims & Hers Health, up from $1.6 billion in the prior quarter.
- In the past five years, Total Non-Current Liabilities ranged from a high of $1.8 billion in Q1 2026 to a low of $53.8 million in Q1 2022.
- The 5-year median for Total Non-Current Liabilities is $103.6 million (2024), against an average of $463.3 million.
- Across the five-year window, Total Non-Current Liabilities slumped 35.02% in 2022 and jumped 1008.31% in 2025, its largest moves.
- Hims & Hers Health's Total Non-Current Liabilities stood at $54.6 million in 2022, then soared by 78.02% to $97.1 million in 2023, then jumped by 137.63% to $230.8 million in 2024, then jumped by 594.06% to $1.6 billion in 2025, then climbed by 12.85% to $1.8 billion in 2026.
- The last three Total Non-Current Liabilities figures came in at $1.8 billion (Q1 2026), $1.6 billion (Q4 2025), and $1.6 billion (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 38.34 Bn | 34.60 Bn | 1.97 Bn | 18.28 Bn |
| 2 | Zoetis | 33.27 Bn | 31.33 Bn | 1.62 Bn | 11.64 Bn |
| 3 | United Therapeutics | 23.75 Bn | 21.60 Bn | 648.10 Mn | 599.10 Mn |
| 4 | Aurora Cannabis | 17.11 Bn | 17.03 Bn | 33.43 Mn | 44.12 Mn |
| 5 | Neurocrine Biosciences | 16.37 Bn | 15.05 Bn | 800.70 Mn | 1.24 Bn |
| 6 | Elanco Animal Health | 11.78 Bn | 11.35 Bn | 785.00 Mn | 6.26 Bn |
| 7 | Alkermes | 7.05 Bn | 6.54 Bn | -116.06 Mn | 2.44 Bn |
| 8 | Lantheus Holdings | 6.49 Bn | 5.99 Bn | 230.92 Mn | 1.13 Bn |
| 9 | Hims & Hers Health | 6.19 Bn | 5.44 Bn | 396.79 Mn | 1.81 Bn |
| 10 | Liquidia | 5.63 Bn | 5.40 Bn | 121.79 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.81 Bn |
| Dec 31, 2025 | 1.60 Bn |
| Sep 30, 2025 | 1.65 Bn |
| Jun 30, 2025 | 1.31 Bn |
| Mar 31, 2025 | 340.01 Mn |
| Dec 31, 2024 | 230.82 Mn |
| Sep 30, 2024 | 162.21 Mn |
| Jun 30, 2024 | 118.51 Mn |
| Mar 31, 2024 | 103.60 Mn |
| Dec 31, 2023 | 97.14 Mn |
| Sep 30, 2023 | 85.30 Mn |
| Jun 30, 2023 | 69.81 Mn |
| Mar 31, 2023 | 59.58 Mn |
| Dec 31, 2022 | 54.57 Mn |
| Sep 30, 2022 | 71.14 Mn |
| Jun 30, 2022 | 59.40 Mn |
| Mar 31, 2022 | 53.81 Mn |
| Dec 31, 2021 | 83.97 Mn |
| Sep 30, 2021 | 63.70 Mn |
| Jun 30, 2021 | 29.24 Mn |